Follow-up and hormone substitution after ovarian cancer;Nachsorge und hormon-substitution nach ovarialkarzinom

Onkologe

Volumn 8, Issue 11, 2002, Pages 1230-1235

  Stahle A ^a   Emons, G ^b   Kuhnle H ^c  

^a St Vincentius Krankenhauser   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; HORMONE;

CLINICAL FEATURE; FOLLOW UP; GERMANY; HORMONE SUBSTITUTION; HUMAN; MEDICAL LITERATURE; OVARY CARCINOMA; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036876037     PISSN: 09478965     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00761-002-0423-8     Document Type: Review

References (35)

1. Duk LM, Kauer FM, Fleuren GJ, de Bruijn HW (1989) Serum CA 125 levels in patients with a provisional diagnosis of pelvic inflammatory disease. Clinical and theoretical implications. Acta Obstet Gynecol Scand 68:637-641
2. Kainz C, Prayer L, Gitsch G, Stiglbauer R, Kramer J, Reinthaller A, Kölbl H (1994) The diagnostic value of magnetic resonance imaging for the detection of tumor recurrence in patients with carcinoma of the ovaries. J Am Coll Surg 178:239-244
3. De Rosa V, Mangioni di Stefano ML, Brunetti A, Caraco C, Graziano R, Gallo MS, Maffeo A (1995) Computed tomography and second-look surgery in ovarian cancer patients: correlation, actual role and limitations of CT scan. Eur J Gynaecol Oncol 16:123-129
4. Ilverman PM, Osborne M, Dunnick NR, Brandy LC (1988) CT prior to second-look operation in ovarian cancer. Am J Roentgenol 150:829-832
5. Aravantinos D, Michalas S, Papazefkos V, Christoforaki M, Stypsaneli A, Vlachos G, Athanasiadis P (1990) Predictive values of CA 125 antigen levels and CT scan in second-look procedures for ovarian cancer. Eur J Obstet Gynecol Reprod Biol 37:265-270
6. Forstner R, Hricak H, Powell CB, Azizi L, Frankel SB, Stern JL (1995) Ovarian cancer recurrence: value of MR imaging. Radiology 196:715-720
7. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC (2002) Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma. Gynecol Oncol 85:53-58
8. Cho SM, Ha HK, Byun JY, Lee JM, Kim CJ, Nam-Koong SE, Lee JM (2002) Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. Am J Roentgenol 179:391-395
9. Podratz KC, Cliby WA (1994) Second look surgery in the management of epithelial ovarian cancer. Gynecol Oncol 55:125-733
10. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887
11. Krebs H, Goplerud DR, Kilpatrick SJ, Myers MB, Hunt A (1986) Role of CA 125 as tumor marker in ovarian carcinoma. Obstet Gynecol 67:473-477
12. Markman M (1994) Follow-up of the asymptomatic patient with ovarian cancer. Gynecol Oncol 55:134-137
13. Niloff JM, Knapp RC, Lavin PT (1986) The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 155:56
14. Koelbl H, Schieder K, Neunteufel W, Bieglmayer C (1988) CA 125 in the follow up of patients with ovarian cancer. Eur J Obstet Gynecol REPROD Biol 27:335-342
15. Meier W, Stieber P, Fateh-Moghadam A, Eiermann W, Hepp H (1987) CA 125 in gynecologic malignancies. Eur J Cancer Clin Oncol 23:713-717
16. Hogberg T, Kagedal B (1992) Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125. Gynecol Oncol 46(2):191-198
17. Meier W, Baumgartner L, Stieber P, Hasholzner U, Fateh-Moghadam A (1997) CA 125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Res 17:3019-3020
18. Vergote IB, Bormer OP, Abeler VM (1987) Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Gynecol Oncol 157:88-92
19. Cruickshank DJ, Terry PB, Fullerton WT (1991) The potential value of CA 125 as a tumour marker in small volume, non-evaluable epithelial ovarian cancer. Int J Biol Markers 6:247
20. Van der Burg MEL, Lammes FB, Verweij J (1990) The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1:301-302
21. Gallagher CJ, Ostle P, Bowles J (1994 CA 125 surrogate marker of response and indication for a trial of the early treatment of relapse, abstract. Proc Ann Meet Am Soc Clin Oncol 13:A871
22. Niloff JM, Bast RC, Schaetzl EM, Knapp RC (1985) Text Indent Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 151:981-986
23. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM, Bast RC Jr (1986) CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 67:685-689
24. Eisenhauer EA, Vermorken JB, van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8:963-968
25. Riedinger JM, Coudert B, Barillot I, Buffenoir G, Mayer F, Fargeot P, Cuisenier J, Guerrin J (1997) Intérêt clinique de l'estimation de la vitesse de croissance des récidives ovariennes premières par le temps de doublement du CA 125. Bull Cancer 84:855-860
26. Gore M (2001) Relapsed ovarian cancer in ASCO Educational Book 37th annual meeting, 468-476
27. Riman T, Dickman PW, Nilsson S, Correia N, Nordliner H, Magnus CM, Persson IR (2002) Risk factors for invasive epithelial ovarian cancer: result from a Swedish case-control study. Am J Epidemiol 156:363-373
28. Markman M, Iseminger KA, Hatch KD, Creasman ET, Barnes W, Dubeshter B (1996) Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 62:4-6
29. Eeles RA, Tan S, Wiltshaw, E Fryatt I, A'Hern RP, Shepherd JH, Hamer CL, Blake PR, Chilvers CE (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302:259-262
30. Ursic-Vrscaj M, Bebar S, Zakelj MP (2001) Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 8:70-75
31. Guidozzi F, Daponte A (1999) Estrogen replacement therapy for ovarian carcinoma survivors. A randomised controlled trial. Cancer 86:1013-1018
32. Kuhn W, Meier W (1998) Nachsorge. In: Tumorzentrum München (Hrsg) Maligne Ovarialtumoren, Schriftenreihe des Tumorzentrums München, S 60
33. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M (2001) Oxford centre of Evidence-based Medicine Levels of Evidence and Grades of Recommendation
34. Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC (2002) Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 86:200-211
35. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288(3):368-369